Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether the use of lenzilumab in addition to
current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS)
and improve ventilator-free survival in hospitalized subjects with severe or critical
COVID-19 pneumonia.